365 related articles for article (PubMed ID: 11060782)
1. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
3. Histone acetylation and the cell-cycle in cancer.
Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
7. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
8. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
9. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
10. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Facchinetti MM; De Siervi A; Toskos D; Senderowicz AM
Cancer Res; 2004 May; 64(10):3629-37. PubMed ID: 15150122
[TBL] [Abstract][Full Text] [Related]
11. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes.
Singh RP; Agarwal C; Agarwal R
Carcinogenesis; 2003 Mar; 24(3):555-63. PubMed ID: 12663518
[TBL] [Abstract][Full Text] [Related]
12. E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes.
Parreño M; Garriga J; Limón A; Albrecht JH; Graña X
Oncogene; 2001 Aug; 20(35):4793-806. PubMed ID: 11521191
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
14. A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130.
Garriga J; Jayaraman AL; Limón A; Jayadeva G; Sotillo E; Truongcao M; Patsialou A; Wadzinski BE; Graña X
Cell Cycle; 2004 Oct; 3(10):1320-30. PubMed ID: 15467457
[TBL] [Abstract][Full Text] [Related]
15. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
16. Complexities in the development of cyclin-dependent kinase inhibitor drugs.
Sausville EA
Trends Mol Med; 2002; 8(4 Suppl):S32-7. PubMed ID: 11927285
[TBL] [Abstract][Full Text] [Related]
17. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
18. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
20. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Santamaria D; Ortega S
Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
